TY - JOUR
T1 - Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes
AU - Álvarez-Guisasola, Fernando
AU - Orozco-Beltrán, Domingo
AU - Cebrián-Cuenca, Ana M.
AU - Ruiz Quintero, Manuel Antonio
AU - Angullo Martínez, Escarlata
AU - Ávila Lachica, Luis
AU - Ortega Millán, Carlos
AU - Caride Miana, Elena
AU - Navarro-Pérez, Jorge
AU - Sagredo Perez, Julio
AU - Barrot de la Puente, Joan
AU - Cos Claramunt, Francesc Xavier
PY - 2019/8/1
Y1 - 2019/8/1
N2 - © 2019 Treatment of diabetes mellitus type 2 (DM2) includes healthy eating and exercise (150 minutes/week) as basic pillars. For pharmacological treatment, metformin is the initial drug except contraindication or intolerance; in case of poor control, 8 therapeutic families are available (6 oral and 2 injectable) as possible combinations. An algorithm and some recommendations for the treatment of DM2 are presented. In secondary cardiovascular prevention, it is recommended to associate an inhibitor of the sodium-glucose cotransporter type 2 (iSGLT2) or a glucagon-like peptide-1 receptor agonist (arGLP1) in patients with obesity. In primary prevention if the patient is obese or overweight metformin should be combined with iSGLT2, arGLP1, or inhibitors of type 4 dipeptidylpeptidase (iDPP4). If the patient does not present obesity, iDPP4, iSGLT2 or gliclazide, sulfonylurea, recommended due to its lower tendency to hypoglycaemia, may be used.
AB - © 2019 Treatment of diabetes mellitus type 2 (DM2) includes healthy eating and exercise (150 minutes/week) as basic pillars. For pharmacological treatment, metformin is the initial drug except contraindication or intolerance; in case of poor control, 8 therapeutic families are available (6 oral and 2 injectable) as possible combinations. An algorithm and some recommendations for the treatment of DM2 are presented. In secondary cardiovascular prevention, it is recommended to associate an inhibitor of the sodium-glucose cotransporter type 2 (iSGLT2) or a glucagon-like peptide-1 receptor agonist (arGLP1) in patients with obesity. In primary prevention if the patient is obese or overweight metformin should be combined with iSGLT2, arGLP1, or inhibitors of type 4 dipeptidylpeptidase (iDPP4). If the patient does not present obesity, iDPP4, iSGLT2 or gliclazide, sulfonylurea, recommended due to its lower tendency to hypoglycaemia, may be used.
KW - Antidiabetic drugs
KW - Hyperglycemia
KW - Type 2 diabetes
U2 - https://doi.org/10.1016/j.aprim.2019.05.014
DO - https://doi.org/10.1016/j.aprim.2019.05.014
M3 - Article
C2 - 31320123
VL - 51
SP - 442
EP - 451
ER -
